COL1A1 and Hepatic fibrosis: Immunohistochemical staining revealed that the increased expression of liver fibrosis markers (α-SMA and COL1A1) in the fibrotic septa of the DDC group was decreased in the YCZFD treatment group (Figures 2C, D).